Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Active, not recruiting · Phase 1 · NCT03313778
Conditions: Solid Tumors
At a glance
- Research payments reported, 2025
- $36,827
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 161
About the trial
- Sponsor
- ModernaTX, Inc. (with Merck Sharp & Dohme LLC)
- Tested
- mRNA-4157 (biological), Pembrolizumab (biological), SoC Treatment (biological)
- Dates
- Started 2017-08-14; completion 2027-11-21
- Results posted
- Not yet
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $36,827 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ny Univ School of Medicine $24,377
- Dana Farber Cancer Institute Inc $12,356
- Moffitt Cancer Center $94
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.